{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T17:02:04Z","timestamp":1770742924929,"version":"3.49.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Biohaven Pharmaceuticals, Inc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s40120-024-00708-4","type":"journal-article","created":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T19:03:40Z","timestamp":1736795020000},"page":"527-545","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Measurement Properties of the Friedreich Ataxia Rating Scale in Patients with Spinocerebellar Ataxia"],"prefix":"10.1007","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct03701399","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7389-3354","authenticated-orcid":false,"given":"Michele H.","family":"Potashman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3233-3147","authenticated-orcid":false,"given":"Evan","family":"Popoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4329-5166","authenticated-orcid":false,"given":"Lauren C.","family":"Powell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa Wolfe","family":"Beiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ainsley","family":"Mackenzie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vlad","family":"Coric","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8052-9240","authenticated-orcid":false,"given":"Sub","family":"Subramony","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2280-7273","authenticated-orcid":false,"given":"Matthis","family":"Synofzik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0706-5125","authenticated-orcid":false,"given":"Jeremy","family":"Schmahmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5196-003X","authenticated-orcid":false,"given":"Gilbert","family":"L\u2019Italien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,13]]},"reference":[{"issue":"5","key":"708_CR1","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1007\/s00415-021-10874-2","volume":"269","author":"KH Yap","year":"2022","unstructured":"Yap KH, Azmin S, Che Hamzah J, Ahmad N, van de Warrenburg B, Mohamed IN. Pharmacological and non-pharmacological management of spinocerebellar ataxia: a systematic review. J Neurol. 2022;269(5):2315\u201337. https:\/\/doi.org\/10.1007\/s00415-021-10874-2.","journal-title":"J Neurol"},{"issue":"3","key":"708_CR2","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s12311-015-0687-3","volume":"15","author":"F Bodranghien","year":"2016","unstructured":"Bodranghien F, Bastian A, Casali C, et al. Consensus paper: revisiting the symptoms and signs of cerebellar syndrome. Cerebellum. 2016;15(3):369\u201391. https:\/\/doi.org\/10.1007\/s12311-015-0687-3.","journal-title":"Cerebellum"},{"issue":"2","key":"708_CR3","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s00415-018-9076-4","volume":"266","author":"R Sullivan","year":"2019","unstructured":"Sullivan R, Yau WY, O\u2019Connor E, Houlden H. Spinocerebellar ataxia: an update. J Neurol. 2019;266(2):533\u201344. https:\/\/doi.org\/10.1007\/s00415-018-9076-4.","journal-title":"J Neurol"},{"issue":"3","key":"708_CR4","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/ene.14094","volume":"27","author":"M Lieto","year":"2020","unstructured":"Lieto M, Riso V, Galatolo D, et al. The complex phenotype of spinocerebellar ataxia type 48 in eight unrelated Italian families. Eur J Neurol. 2020;27(3):498\u2013505. https:\/\/doi.org\/10.1111\/ene.14094.","journal-title":"Eur J Neurol"},{"issue":"7","key":"708_CR5","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1002\/acn3.51370","volume":"8","author":"SM Brooker","year":"2021","unstructured":"Brooker SM, Edamakanti CR, Akasha SM, Kuo SH, Opal P. Spinocerebellar ataxia clinical trials: opportunities and challenges. Ann Clin Transl Neurol. 2021;8(7):1543\u201356. https:\/\/doi.org\/10.1002\/acn3.51370.","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"708_CR6","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41572-019-0074-3","volume":"5","author":"T Klockgether","year":"2019","unstructured":"Klockgether T, Mariotti C, Paulson HL. Spinocerebellar ataxia. Nat Rev Dis Primers. 2019;5(1):24. https:\/\/doi.org\/10.1038\/s41572-019-0074-3.","journal-title":"Nat Rev Dis Primers"},{"issue":"8","key":"708_CR7","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1002\/mds.29559","volume":"38","author":"H Hengel","year":"2023","unstructured":"Hengel H, Pellerin D, Wilke C, et al. As frequent as polyglutamine spinocerebellar ataxias: SCA27B in a large German autosomal dominant ataxia cohort. Mov Disord. 2023;38(8):1557\u20138. https:\/\/doi.org\/10.1002\/mds.29559.","journal-title":"Mov Disord"},{"issue":"15","key":"708_CR8","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1002\/mds.22288","volume":"23","author":"C Globas","year":"2008","unstructured":"Globas C, du Montcel ST, Baliko L, et al. Early symptoms in spinocerebellar ataxia type 1, 2, 3, and 6. Mov Disord. 2008;23(15):2232\u20138. https:\/\/doi.org\/10.1002\/mds.22288.","journal-title":"Mov Disord"},{"issue":"1","key":"708_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1504","volume":"14","author":"D Pellerin","year":"2024","unstructured":"Pellerin D, Danzi MC, Renaud M, et al. Spinocerebellar ataxia 27B: a novel, frequent and potentially treatable ataxia. Clin Transl Med. 2024;14(1): e1504. https:\/\/doi.org\/10.1002\/ctm2.1504.","journal-title":"Clin Transl Med"},{"issue":"4","key":"708_CR10","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/s1474-4422(18)30042-5","volume":"17","author":"A Diallo","year":"2018","unstructured":"Diallo A, Jacobi H, Cook A, et al. Survival in patients with spinocerebellar ataxia types 1, 2, 3, and 6 (EUROSCA): a longitudinal cohort study. Lancet Neurol. 2018;17(4):327\u201334. https:\/\/doi.org\/10.1016\/s1474-4422(18)30042-5.","journal-title":"Lancet Neurol"},{"issue":"5","key":"708_CR11","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1002\/mds.22740","volume":"25","author":"T Schmitz-H\u00fcbsch","year":"2010","unstructured":"Schmitz-H\u00fcbsch T, Coudert M, Giunti P, et al. Self-rated health status in spinocerebellar ataxia\u2014results from a European multicenter study. Mov Disord. 2010;25(5):587\u201395. https:\/\/doi.org\/10.1002\/mds.22740.","journal-title":"Mov Disord"},{"issue":"3","key":"708_CR12","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.nrl.2015.09.002","volume":"32","author":"CR Sanchez-Lopez","year":"2017","unstructured":"Sanchez-Lopez CR, Perestelo-Perez L, Escobar A, Lopez-Bastida J, Serrano-Aguilar P. Health-related quality of life in patients with spinocerebellar ataxia. Neurologia. 2017;32(3):143\u201351. https:\/\/doi.org\/10.1016\/j.nrl.2015.09.002.","journal-title":"Neurologia"},{"issue":"10","key":"708_CR13","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/s41582-018-0051-6","volume":"14","author":"T Ashizawa","year":"2018","unstructured":"Ashizawa T, \u00d6z G, Paulson HL. Spinocerebellar ataxias: prospects and challenges for therapy development. Nat Rev Neurol. 2018;14(10):590\u2013605. https:\/\/doi.org\/10.1038\/s41582-018-0051-6.","journal-title":"Nat Rev Neurol"},{"issue":"3","key":"708_CR14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s11940-019-0549-2","volume":"21","author":"CD Stephen","year":"2019","unstructured":"Stephen CD, Brizzi KT, Bouffard MA, et al. The comprehensive management of cerebellar ataxia in adults. Curr Treat Options Neurol. 2019;21(3):9. https:\/\/doi.org\/10.1007\/s11940-019-0549-2.","journal-title":"Curr Treat Options Neurol"},{"key":"708_CR15","unstructured":"Patient-focused drug development guidance public workshop: incorporating clinical outcome assessments into endpoints for regulatory decision-making. 2019. https:\/\/www.fda.gov\/media\/132505\/download. Accessed 1 Nov 2023"},{"key":"708_CR16","unstructured":"Patient-focused drug development: incorporating clinical outcome assessments into endpoints for regulatory decision-making: guidance for industry, food and drug administration staff, and other stakeholders. 2023. https:\/\/www.fda.gov\/media\/166830\/download. Accessed 1 Nov 2023"},{"key":"708_CR17","unstructured":"Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims (US food and drug administration). (2009). https:\/\/www.fda.gov\/media\/77832\/download. Accessed 1 Nov 2023"},{"issue":"11","key":"708_CR18","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1212\/01.wnl.0000219042.60538.92","volume":"66","author":"T Schmitz-Hubsch","year":"2006","unstructured":"Schmitz-Hubsch T, du Montcel ST, Baliko L, et al. Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology. 2006;66(11):1717\u201320. https:\/\/doi.org\/10.1212\/01.wnl.0000219042.60538.92.","journal-title":"Neurology"},{"issue":"7","key":"708_CR19","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1212\/01.WNL.0000156802.15466.79","volume":"64","author":"SH Subramony","year":"2005","unstructured":"Subramony SH, May W, Lynch D, et al. Measuring Friedreich ataxia: interrater reliability of a neurologic rating scale. Neurology. 2005;64(7):1261\u20132. https:\/\/doi.org\/10.1212\/01.WNL.0000156802.15466.79.","journal-title":"Neurology"},{"issue":"2","key":"708_CR20","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/mds.28313","volume":"36","author":"S Perez-Lloret","year":"2021","unstructured":"Perez-Lloret S, van de Warrenburg B, Rossi M, et al. Assessment of ataxia rating scales and cerebellar functional tests: critique and recommendations. Mov Disord. 2021;36(2):283\u201397. https:\/\/doi.org\/10.1002\/mds.28313.","journal-title":"Mov Disord"},{"key":"708_CR21","unstructured":"ClinicalTrials.gov. Troriluzole in adult subjects with spinocerebellar ataxia. NCT03701399. https:\/\/classic.clinicaltrials.gov\/show\/NCT03701399. Accessed 19 Sept 2023"},{"issue":"6","key":"708_CR22","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1212\/nxg.0000000000000371","volume":"5","author":"C Rummey","year":"2019","unstructured":"Rummey C, Corben LA, Delatycki MB, et al. Psychometric properties of the Friedreich ataxia rating scale. Neurol Genet. 2019;5(6):371. https:\/\/doi.org\/10.1212\/nxg.0000000000000371.","journal-title":"Neurol Genet"},{"issue":"11","key":"708_CR23","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1212\/01.wnl.0000218155.46739.90","volume":"66","author":"DR Lynch","year":"2006","unstructured":"Lynch DR, Farmer JM, Tsou AY, et al. Measuring Friedreich ataxia: complementary features of examination and performance measures. Neurology. 2006;66(11):1711\u20136. https:\/\/doi.org\/10.1212\/01.wnl.0000218155.46739.90.","journal-title":"Neurology"},{"issue":"4","key":"708_CR24","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1002\/mds.22912","volume":"25","author":"LS Friedman","year":"2010","unstructured":"Friedman LS, Farmer JM, Perlman S, et al. Measuring the rate of progression in Friedreich ataxia: implications for clinical trial design. Mov Disord. 2010;25(4):426\u201332. https:\/\/doi.org\/10.1002\/mds.22912.","journal-title":"Mov Disord"},{"key":"708_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/mds.29788","author":"A Traschutz","year":"2024","unstructured":"Traschutz A, Fleszar Z, Hengel H, et al. FARS-ADL across ataxias: construct validity, sensitivity to change, and minimal important change. Mov Disord. 2024. https:\/\/doi.org\/10.1002\/mds.29788.","journal-title":"Mov Disord"},{"key":"708_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/s12311-024-01707-9","author":"M Potashman","year":"2024","unstructured":"Potashman M, Popoff E, Powell L, et al. Psychometric validation of the modified functional scale for the assessment and rating of ataxia (f-SARA) in patients with spinocerebellar ataxia. Cerebellum. 2024. https:\/\/doi.org\/10.1007\/s12311-024-01707-9.","journal-title":"Cerebellum"},{"issue":"4","key":"708_CR27","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/bf01593882","volume":"4","author":"CA McHorney","year":"1995","unstructured":"McHorney CA, Tarlov AR. Individual-patient monitoring in clinical practice: are available health status surveys adequate? Qual Life Res. 1995;4(4):293\u2013307. https:\/\/doi.org\/10.1007\/bf01593882.","journal-title":"Qual Life Res"},{"key":"708_CR28","volume-title":"McGraw-Hill series in psychology","author":"JC Nunnally","year":"1994","unstructured":"Nunnally JC, Bernstein IH. Psychometric theory. In: McGraw-Hill series in psychology. 3rd ed. New York: McGraw-Hill; 1994.","edition":"3"},{"issue":"1","key":"708_CR29","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1081\/copd-200050508","volume":"2","author":"NK Leidy","year":"2005","unstructured":"Leidy NK, Wyrwich KW. Bridging the gap: using triangulation methodology to estimate minimal clinically important differences (MCIDs). COPD. 2005;2(1):157\u201365. https:\/\/doi.org\/10.1081\/copd-200050508.","journal-title":"COPD"},{"key":"708_CR30","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/1477-7525-4-70","volume":"4","author":"DA Revicki","year":"2006","unstructured":"Revicki DA, Cella D, Hays RD, Sloan JA, Lenderking WR, Aaronson NK. Responsiveness and minimal important differences for patient reported outcomes. Health Qual Life Outcomes. 2006;4:70. https:\/\/doi.org\/10.1186\/1477-7525-4-70.","journal-title":"Health Qual Life Outcomes"},{"key":"708_CR31","doi-asserted-by":"crossref","unstructured":"Potashman M, Rudell K, Suminski N, Doma R, Heinrich M, Abetz-Webb L, et al. Content validity of the Friedreich Ataxia Rating Scale in patients with spinocerebellar ataxia. Neurol Ther. 2024 (in press)","DOI":"10.1007\/s40120-024-00704-8"},{"issue":"11","key":"708_CR32","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/s1474-4422(15)00202-1","volume":"14","author":"H Jacobi","year":"2015","unstructured":"Jacobi H, du Montcel ST, Bauer P, et al. Long-term disease progression in spinocerebellar ataxia types 1, 2, 3, and 6: a longitudinal cohort study. Lancet Neurol. 2015;14(11):1101\u20138. https:\/\/doi.org\/10.1016\/s1474-4422(15)00202-1.","journal-title":"Lancet Neurol"},{"issue":"2","key":"708_CR33","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/jns.12538","volume":"28","author":"TT Wu","year":"2023","unstructured":"Wu TT, Finkel RS, Siskind CE, et al. Validation of the parent-proxy pediatric Charcot-Marie-Tooth disease quality of life outcome measure. J Peripher Nerv Syst. 2023;28(2):237\u201351. https:\/\/doi.org\/10.1111\/jns.12538.","journal-title":"J Peripher Nerv Syst"},{"issue":"1","key":"708_CR34","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12955-023-02154-6","volume":"21","author":"L Ambrosio","year":"2023","unstructured":"Ambrosio L, Hislop-Lennie K, Serrano-Fuentes N, Driessens C, Portillo MC. First validation study of the living with long term conditions scale (LwLTCs) among English-speaking population living with Parkinson\u2019s disease. Health Qual Life Outcomes. 2023;21(1):69. https:\/\/doi.org\/10.1186\/s12955-023-02154-6.","journal-title":"Health Qual Life Outcomes"},{"issue":"5","key":"708_CR35","doi-asserted-by":"publisher","first-page":"443","DOI":"10.6061\/clinics\/2012(05)07","volume":"67","author":"HA Teive","year":"2012","unstructured":"Teive HA, Munhoz RP, Arruda WO, et al. Spinocerebellar ataxias: genotype-phenotype correlations in 104 Brazilian families. Clinics (Sao Paulo). 2012;67(5):443\u20139. https:\/\/doi.org\/10.6061\/clinics\/2012(05)07.","journal-title":"Clinics (Sao Paulo)"},{"issue":"12","key":"708_CR36","doi-asserted-by":"publisher","first-page":"5756","DOI":"10.1007\/s00415-023-11993-8","volume":"270","author":"N Urbini","year":"2023","unstructured":"Urbini N, Siciliano L, Olivito G, Leggio M. Unveiling the role of cerebellar alterations in the autonomic nervous system: a systematic review of autonomic dysfunction in spinocerebellar ataxias. J Neurol. 2023;270(12):5756\u201372. https:\/\/doi.org\/10.1007\/s00415-023-11993-8.","journal-title":"J Neurol"},{"issue":"3","key":"708_CR37","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1136\/practneurol-2018-002096","volume":"19","author":"RNd Silva","year":"2019","unstructured":"Silva RNd, Vallortigara J, Greenfield J, Hunt B, Giunti P, Hadjivassiliou M. Diagnosis and management of progressive ataxia in adults. Prac Neurol. 2019;19(3):196\u2013207. https:\/\/doi.org\/10.1136\/practneurol-2018-002096.","journal-title":"Prac Neurol"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-024-00708-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-024-00708-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-024-00708-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T19:03:45Z","timestamp":1741892625000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-024-00708-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,13]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["708"],"URL":"https:\/\/doi.org\/10.1007\/s40120-024-00708-4","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,13]]},"assertion":[{"value":"13 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Michele Potashman, Ainsley Mackenzie, Melissa Wolfe Beiner, Vlad Coric, and Gilbert L\u2019Italien are employees of Biohaven Pharmaceuticals, Inc. Evan Popoff and Lauren Powell are employees of Broadstreet HEOR, which received funds from Biohaven Pharmaceuticals, Inc, for this work. Sub Subramony has received research support from the National Ataxia Foundation, Biohaven Pharmaceuticals, Inc, National Institutes of Health, US Food and Drug Administration, Muscular Dystrophy Association, Wyck Foundation, Friedreich\u2019s Ataxia Research Alliance, Reata, PTC Therapeutics, Retrotope, Avidity Biosciences, Fulcrum Therapeutics, Reneo Pharma, and AavantiBio; and has served on scientific advisory boards for Reata, Avidity, and Dyne Therapeutics. Matthis Synofzik has received consultancy honoraria from Ionis, UCB, Prevail, Orphazyme, Servier, Reata, GenOrph, AviadoBio, Biohaven, Solaxa, Zevra, and Lilly. Jeremy Schmahmann consults for Biohaven Pharmaceuticals and is site PI for Biohaven Pharmaceuticals clinical trials NCT03701399, NCT02960893, and NCT03952806; receives royalties from Oxford University Press, Elsevier, MacKeith Press, and Springer; and is the inventor of the Brief Ataxia Rating Scale, Cerebellar Cognitive Affective\/Schmahmann Syndrome Scale, the Patient-Reported Outcome Measure of Ataxia, and the Cerebellar Neuropsychiatry Rating Scale, which are licensed to the General Hospital Corporation. He is supported in part by the National Ataxia Foundation, the MINDLink Foundation, and the Raynor Cerebellum Project.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Study 206 (BHV4157-206; NCT03701399) was a multisite study approved by a centralized independent Institutional Review Board (Institutional Review Board; Advarra, Columbia, MD, USA), with additional local Institutional Review Board approvals obtained where requested (per institute). The PROM-Ataxia study (MGH psychometric cohort) was approved by Mass General Brigham Human Research Committee Institutional Review Board (Somerville, MA, USA). Both studies were conducted in accordance with the 1964 Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}